The estimated Net Worth of Keith Westby is at least $8.14 Milion dollars as of 3 July 2023. Mr. Westby owns over 20,000 units of IVERIC bio Inc stock worth over $2,383,097 and over the last 8 years he sold ISEE stock worth over $4,326,140. In addition, he makes $1,434,830 as Chief Operating Officer i Senior Vice President at IVERIC bio Inc.
Sign up
Mr. Westby ISEE stock SEC Form 4 insiders trading
Keith has made over 29 trades of the IVERIC bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of ISEE stock worth $58,800 on 3 July 2023.
The largest trade he's ever made was selling 72,916 units of IVERIC bio Inc stock on 1 November 2022 worth over $1,744,151. On average, Keith trades about 14,087 units every 32 days since 2017. As of 3 July 2023 he still owns at least 59,652 units of IVERIC bio Inc stock.
You can see the complete history of Mr. Westby stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keith Westby biography
Keith Westby serves as Chief Operating Officer, Senior Vice President of the Company. Mr. Westby has served as our senior vice president, chief operating officer since January 2017. Mr. Westby joined us in 2007 and previously served as senior vice president of development operations from October 2014 to January 2017, as vice president, program management and business operations from December 2012 to September 2014 and senior director, project management from August 2007 to December 2012. Prior to joining us, Mr. Westby served as director, project and alliance management at Pharmasset, Inc., a pharmaceutical company, from December 2005 to August 2007. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, Inc. from January 2002 to December 2005, including director, alliance & project management. Earlier in his career, Mr. Westby worked at Tunnell Consulting as a senior consultant. Mr. Westby received a B.S. in physics from the State University of New York, College at Geneseo, an M.S. in engineering management from Drexel University and an M.B.A. from Columbia Business School.
What is the salary of Keith Westby?
As the Chief Operating Officer i Senior Vice President of IVERIC bio Inc, the total compensation of Keith Westby at IVERIC bio Inc is $1,434,830. There are 4 executives at IVERIC bio Inc getting paid more, with Glenn Sblendorio having the highest compensation of $2,462,150.
How old is Keith Westby?
Keith Westby is 45, he's been the Chief Operating Officer i Senior Vice President of IVERIC bio Inc since 2017. There are 14 older and no younger executives at IVERIC bio Inc. The oldest executive at IVERIC bio Inc is Calvin Roberts, 67, who is the Independent Director.
What's Keith Westby's mailing address?
Keith's mailing address filed with the SEC is C/O IVERIC BIO, INC., 8 SYLVAN WAY, PARSIPPANY, NJ, 07054.
Insiders trading at IVERIC bio Inc
Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver... oraz Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.
What does IVERIC bio Inc do?
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
What does IVERIC bio Inc's logo look like?
Complete history of Mr. Westby stock trades at IVERIC bio Inc
IVERIC bio Inc executives and stock owners
IVERIC bio Inc executives and other stock owners filed with the SEC include:
-
Glenn Sblendorio,
President, Chief Executive Officer, Director -
David Guyer,
Executive Chairman of the Board -
Anthony S. Gibney,
Exec. VP and Chief Bus. & Strategy Officer -
David Carroll,
Chief Financial Officer, Senior Vice President, Treasurer -
Keith Westby,
Chief Operating Officer, Senior Vice President -
Glenn P. Sblendorio M.B.A.,
CEO & Director -
Dr. Pravin U. Dugel M.D.,
Pres -
David F. Carroll M.B.A.,
Sr. VP, CFO & Treasurer -
Christopher Paul Simms,
Sr. VP & Chief Commercial Officer -
David F. Carroll,
Sr. VP, CFO & Treasurer -
Keith Westby M.B.A.,
Sr. VP & COO -
Calvin Roberts,
Independent Director -
Jane Henderson,
Independent Director -
Adrienne Graves,
Lead Independent Director -
Axel Bolte,
Independent Director -
Kathy Galante,
Vice President, Investor Relations and Corporate Communications -
Mark Blumenkranz,
Director -
Abraham Scaria,
Chief Scientific Officer -
Evelyn Harrison,
Sr. VP & Chief Clinical Operations Officer -
Amy R. Sheehan,
Sr. VP & Chief HR Officer -
Todd D.C. Anderman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Xiao-Ping Dai Ph.D.,
Chief Technical Officer -
Dr. Samir C. Patel,
Co-Founder and Consultant -
Christopher Paul Simms,
SVP, Chief Commercial Officer -
Christine Ann Miller,
Director -
David E Redlick,
Director -
Venture Capital Iv, L.P.Ver...,
-
Anthony S Gibney,
EVP, Chief Business Officer -
Pravin Dugel,
President